Cargando…

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis

OBJECTIVES: To retrospectively compare long-term outcomes of first-line drug-eluting particle (DEB)- transarterial chemoembolization (TACE) and lipiodol-TACE, in patients with unresectable hepatocellular (HCC). METHODS: We retrospectively reviewed our database to identify adult patients with treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bargellini, Irene, Lorenzoni, Valentina, Lorenzoni, Giulia, Scalise, Paola, Andreozzi, Gianni, Bozzi, Elena, Giorgi, Luigi, Cervelli, Rosa, Scandiffio, Rossella, Perrone, Orsola, Meccia, Donato Vito, Boccuzzi, Antonio, Daviddi, Francesco, Cicorelli, Antonio, Lunardi, Alessandro, Crocetti, Laura, Turchetti, Giuseppe, Cioni, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Interventional
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452560/ https://www.ncbi.nlm.nih.gov/pubmed/33871708 http://dx.doi.org/10.1007/s00330-021-07905-x

Ejemplares similares

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
por: Wiggermann, Philipp, et al.
Publicado: (2011)

Portal Vein Damage after DEB-TACE and Lipiodol-TACE: Based on Evaluation by Computed Tomography during Arterial Portography
por: Tamura, Masashi, et al.
Publicado: (2021)

Spontaneous Bleedings in COVID-19 Patients: An Emerging Complication
por: Bargellini, Irene, et al.
Publicado: (2020)

The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT
por: Sun, HongLiang, et al.
Publicado: (2017)

DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center
por: Luz, Jose Hugo Mendes, et al.
Publicado: (2017)

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study
por: Wang, Junxiao, et al.
Publicado: (2023)

Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients
por: Zhu, Dedong, et al.
Publicado: (2019)

Neuroendocrine Tumor Treated with Arterial Chemoembolization Using DEB-TACE
por: Suzuki, Ko, et al.
Publicado: (2019)

Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients
por: Li, Ningjie, et al.
Publicado: (2022)

Locoregional Treatments for Bridging and Downstaging HCC to Liver Transplantation
por: Crocetti, Laura, et al.
Publicado: (2021)

Efficacy and Safety of Combined Ethanol-Lipiodol Mixture and Drug-Eluting Bead TACE for Large HCC
por: Chuang, Yi-Hsuan, et al.
Publicado: (2023)

DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC
por: Kondo, Yasuteru, et al.
Publicado: (2022)

Transradial versus transfemoral arterial access in DEB-TACE for hepatocellular carcinoma
por: Ghosh, Abheek, et al.
Publicado: (2022)

Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response
por: Dioguardi Burgio, Marco, et al.
Publicado: (2019)

Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study
por: Li, Baojian
Publicado: (2022)

Retracted: Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study
por: Healthcare Engineering, Journal of
Publicado: (2023)

Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
por: Scartozzi, Mario, et al.
Publicado: (2010)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study
por: Xiang, Hua, et al.
Publicado: (2019)

Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
por: Bi, Yonghua, et al.
Publicado: (2023)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Performance and Safety of a Reflux-Control Microcatheter Used to Perform DEB-TACE with LUMI(TM) Beads in HCC Patients: Preliminary Experience
por: Angileri, Salvatore Alessio, et al.
Publicado: (2023)

Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis
por: Andreozzi, G., et al.
Publicado: (2023)

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma
por: Huang, Dexiao, et al.
Publicado: (2017)

Evaluation of the Safety and Efficacy of Conventional Transarterial Chemoembolization (cTACE) and Drug-Eluting Bead (DEB)-TACE in the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review
por: Ayyub, Javaria, et al.
Publicado: (2023)

Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20–40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm
por: Cho, Su Min, et al.
Publicado: (2021)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE
por: Chai, Bin, et al.
Publicado: (2022)

The Role of Conventional TACE (cTACE) and DEBIRI-TACE in Colorectal Cancer Liver Metastases
por: Vogl, Thomas J., et al.
Publicado: (2022)

COCH predicts survival and adjuvant TACE response in patients with HCC
por: Wang, Chen, et al.
Publicado: (2021)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
por: Huang, Wei, et al.
Publicado: (2022)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)?
por: Somma, Francesco, et al.
Publicado: (2015)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
por: Kinzler, Maximilian N., et al.
Publicado: (2023)

Quantitative analysis with multiphase contrast-enhanced computed tomography to evaluate residual tumor activity of hepatocellular carcinoma after DEB-TACE
por: Hu, Wenchao, et al.
Publicado: (2023)

Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?
por: Ge, Naijian, et al.
Publicado: (2023)

The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT)
por: Yang, Ping, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mf856vmbrql4iera8tvnpkfor7